12:00 AM
Oct 05, 2009
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Cellceutix preclinical data

In mice subcutaneously implanted with taxane-resistant, estrogen receptor-negative human breast cancer cells, Kevetrin significantly reduced tumor volume and delayed tumor growth compared with paclitaxel...

Read the full 97 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >